| Literature DB >> 20843349 |
Jason W Johnston1, Haider Shamsulddin, Anne-Frances Miller, Michael A Apicella.
Abstract
BACKGROUND: The transport and catabolism of sialic acid, a critical virulence factor for nontypeable Haemophilus influenzae, is regulated by two transcription factors, SiaR and CRP.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20843349 PMCID: PMC2946308 DOI: 10.1186/1471-2180-10-240
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1The sialic acid catabolic and transport operons and pathway. A. Schematic diagram of the nan and siaPT operons. The nan operon encodes for the entire catabolic pathway and the transcriptional regulator SiaR. The siaPT operon encodes for the sialic acid transporter and YjhT, a sialic acid mutarotase. The accession numbers for the KW-20 Rd sequence are indicated below each gene. B. The sialic acid catabolic pathway.
Figure 2Primer extension analysis of the . Complement of sequence surrounding the transcriptional start sites included with the sites indicated in bold and with asterisks. A. Primer extension analysis identified at least two major transcriptional start sites for the nan operon. Two bands were present for TS-2as indicated. B. Primer extension identified one start site for the siaPT operon. C. Schematic diagram of the nan and siaPT promoters. Binding sites for SiaR (red box) and CRP (blue box) are indicated as well as putative -10 boxes for TS-1and TS-1(yellow boxes).
Figure 3Impact of metabolic impairment on the expression of . 2019ΔcyaA and derived double mutants were grown in sRPMI. Sialic acid and cAMP were added 30 min prior to RNA extraction. Expression of nanE and siaP were measured by qRT-PCR. Results are presented as fold change relative to a culture that received neither sialic acid nor cAMP.
Figure 4Expression of . Cultures grown with sialic acid (open bars), cAMP (gray bars), and both sialic acid and cAMP (black bars) were compared to a reference culture that received neither.
Figure 5Expression of . Expression of nanE and siaP in 2019ΔcyaA (A), 2019ΔcyaA ΔnagB (B), 2019ΔcyaA+5 bp (C), and 2019ΔcyaA ΔnagB+5 bp (D). Cultures grown with sialic acid (open bars), cAMP (gray bars), and both sialic acid and cAMP (black bars) were compared to a reference culture that received neither.
Figure 6Electrophoretic mobility shift assay. A. Binding of both SiaR and CRP to the nan-siaPT intergenic region. Both SiaR and CRP bind to the probe individually and CRP binding is dependent on the presence of cAMP. Both proteins bind the probe simultaneously as indicated by the higher shift of the probe when both proteins are added. B. GlcN-6P enhances binding of SiaR. Two-fold serial dilutions of SiaR were added to binding reactions in the absence and presence of 100 μM GlcN-6P. More probe was shifted when GlcN-6P was present.
Figure 7Detection of intracellular GlcN-6P by P NMR spectroscopy. 31P NMR spectra were obtained following the growth of cells in the presence of exogenous cAMP and/or Neu5Ac. A. 2019ΔcyaA ΔnagB with Neu5Ac and cAMP. B. 2019 wild-type with Neu5Ac and cAMP. C. 2019ΔcyaA ΔnagB with cAMP. D. 2019 wild-type with cAMP. E. 2019 wild-type without supplement.
Figure 8Model of SiaR and CRP regulation of the . A. In the absence of sialic acid and cAMP, SiaR is bound to its operator and expression of the nan and siaPT operons is repressed. B. When cAMP is present, CRP binds to its operator and is able to activate the siaPT operon, but not the nan operon. C. When both GlcN-6P and cAMP are present, SiaR and CRP are active and interact to form a complex that activates both the nan and siaPT operons. D. In helical phasing experiments, insertion of one half-turn in between the SiaR and CRP operators prevents the regulators from interacting and thus maximal activation of the nan operon is not achieved.
Strains and plasmids
| Strain or plasmid | Genotype, relevant phenotype or selection marker | Source or reference |
|---|---|---|
| Strains | ||
| Invitrogen | ||
| E. coli BL21 Star | Invitrogen | |
| NTHi 2019 | Clinical respiratory isolate | [ |
| JWJ091 | NTHi 2019Δ | This study |
| JWJ093 | NTHi 2019Δ | This study |
| JWJ112 | NTHi 2019Δ | This study |
| JWJ114 | NTHi 2019Δ | This study |
| JWJ116 | NTHi 2019Δ | This study |
| JWJ118 | NTHi 2019Δ | This study |
| JWJ120 | NTHi 2019Δ | This study |
| JWJ159 | NTHi 2019Δ | This study |
| JWJ160 | NTHi 2019Δ | This study |
| Plasmids | ||
| pGEM-T Easy | PCR-cloning vector | Promega |
| pGEM-T | PCR-cloning vector | Promega |
| pCR2.1 | PCR-cloning vector | Invitrogen |
| pCR2.1_443 | pCR2.1 with PCR fragment spanning | This study |
| pUC19 | General cloning vector | New England Biolabs |
| pET-24(+) | Expression vector | Novagen |
| pUC19-142del | This study | |
| pUC19-142 | This study | |
| pJJ150 | [ | |
| pJJ185 | C-terminal his-tagged SiaR expression vector | [ |
| pJJ260 | ||
| pJJ276 | C-terminal his-tagged CRP expression vector | This study |
| pJJ279 | This study | |
| pJJ290 | This study | |
| pJJ308 | This study | |
| pJJ309 | This study | |
| pJJ310 | This study | |
| pJJ311 | This study | |
| pJJ313 | This study | |
| pJJ314 | This study | |
| pJJ315 | This study | |
| pJJ316 | This study | |
| pJJ321 | pCR2.1_443 with 5 bp deletion | This study |
| pJJ331 | pJJ321 with | This study |
Oligonucleotide primers
| Oligonucleotide primer | Use | |
|---|---|---|
| 140F3 | gaa ttc CTG CTT CTT CAT TAA GTT CTC GC | |
| 140R5 | ccc ggg CAT ATT CTG TTC CTA ATA TCA ACA TCA GTT | |
| 140F6 | ccc ggg TAA TAG TAA ACA CTT AAA TAG TTA ATT GAT TTA AAA ATC | |
| 140R6 | gca tgc TCA AAA ACA GCA ACA CGG TGC | |
| 141F1 | gaa ttc CAT CAT CGC TGA AAC AGG C | |
| 141R3 | ccc ggg CAT ATT AGC CTT CCT TTA TTA TTG ACC G | |
| 141F3 | ccc ggg TAG AGA TCT ATT CTT CAT CTT TAT GTA GGG | |
| 141R4 | gca tgc GGT TTC AAC GCT AGT TTG GTC G | |
| 144F1 | gaa ttc CCG TCC TTT TGT GAA TGT CC | |
| 144F3 | ccc ggg CAT AAC TTA TCC TTA TAG TGT AAA GTC TTT TCT CAC | |
| 144F2 | ccc ggg AAG CCT GAA GGA ACA ATT TAT GGC TAA | |
| 144R2 | gca tgc GCC GTT TCA GCA GAA TAA CCA G | |
| 145F5 | gaa ttc CGC TCC TGT GTG AAC TTA TG | |
| 145R5 | ccc ggg CAT ATA ACA CCC CTC ATT TAA ATC TGA AT | |
| 145F6 | ccc ggg TAG TCG TAA GAC GTG TGA GAA AAG ACT T | |
| 145R6 | gca tgc CGA ACG CAA AAT CGT ATC GGC | |
| 604F1 | gag ctc CAT TTT GCT GAC GAG GAA CTG | |
| 604R1 | ccc ggg CAT TAC ATA AAC ACC TAA AAT TGG TGG | |
| 604F2 | ccc ggg TAA TAT TTT CCT GTG GTT GAT AGG TTA CC | |
| 604R2 | aag ctt AAA GCA ATG GAG TGG ACC ACA ATT | |
| 145R8 | CCG CAG CAA TTT TTG TCC | PCR SOEing |
| 145M2 | TTT ATG AAA AAA CAC TTC AAA AAT | PCR SOEing |
| 145M3 | ATT TTT GAA GTG TTT TTT CAT AAA | PCR SOEing |
| 146R2 | CCA TTA CGG CAC ACT AAA GAG G | PCR SOEing |
| 957F2 | aag ctt AAT AAA ACG GAA TTT TTG AAA CAG G | CRP expression |
| 957R2 | ctc gag TCT TGC GCC ATA TAC AAC GAT TGT | CRP expression |
| P146F1 | ACA CCC CTC ATT TAA ATC TGA ATA AAT CAC | EMSA |
| P146R4 | CCC CCA AAA TAG GAT TCG | EMSA |
| 145R7 | CGA CAG GTT GGC AAG AAG AAA TAA GAC C | Primer extension |
| 145R1 | ATC AGC GGC AAG AAC AGC AG | Primer extension |
1Restriction sites added to aid in subcloning are indicated by lowercase letters. Bases added for 5 bp insertion are italicized.